Claritev
Claritev's revenue rose 3.7% to $965 million in fiscal 2025. Its operating margin was 3.0%, up from −149.3% a year earlier. Free cash flow was −$12 million. The diluted share count rose 1.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Claritev does
Claritev, formerly known as MultiPlan, is a technology, data and analytics company that works on healthcare costs and billing. It sells its services mainly to health insurers and other payers, employers that fund health plans, and the plan members and providers connected to them. It was founded in 1980.
Its main services help payers manage the cost of out-of-network claims, which are bills from doctors and hospitals outside a plan's network, and check that both in-network and out-of-network claims are billed and paid correctly. It often does this before the claim is paid. A portion of the revenue from its claims intelligence solutions is based on a percentage of the price concessions from providers on claims of its payer clients.
The company has also entered new areas, including payer risk analytics and network transparency and analytic services. It says it has put over $500 million into capitalized software development in the past five years, and it is pursuing a plan it calls Vision 2030.
Its biggest risks, as it describes them
- Losing key clients or depending on a core group of clients for much of its revenue.
- Failing to gain the benefits it expects from its Vision 2030 plan or from entering new lines of business.
- Not having enough cash or liquidity to run the business and meet its obligations.
- Competition and pricing pressure in a fragmented market.
- Changes in the healthcare industry, and legal claims it may face.
Income statement
From fiscal 2018 to 2021, earnings per share grew 21.1% a year and net income 41.3% a year, as new shares raised the share count by 57% and diluted each share's earnings. Claritev then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 185 | 334 | 72 | 17 | 17 |
| Debt incl. finance leases | 4,972 | 4,822 | 4,600 | 4,566 | 4,612 |
| Net debt (negative means net cash) | 4,786 | 4,488 | 4,528 | 4,549 | 4,595 |
| Net debt to EBITDA | 6.0x | 96.4x | 7.8x | — | 9.7x |
| Debt to equity | 2.1x | 2.7x | 2.7x | — | — |
| Interest coverage | 1.4x | −1.2x | 0.5x | −4.3x | 0.1x |
| Current ratio | 2.2x | 2.5x | 1.2x | 0.8x | 0.9x |
| Quick ratio | 2.2x | 2.5x | 1.2x | 0.8x | 0.9x |
Cash flow
Projections
Project Claritev's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 6 insiders bought $1.9 million of Claritev shares on the open market, and 3 insiders sold $919,352, $276,055 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Douglas Michael GarisEvp&cfo | Sold plan | 9,025 | $30.59 | $276,055 | Form 4 |
| Aug 28, 2026 | Travis DaltonPres., CEO & Executive Chair, Director | Bought | 1,950 | $38.48 | $75,036 | Form 4 |
| Aug 27, 2026 | Travis DaltonPres., CEO & Executive Chair, Director | Bought | 4,500 | $38.81 | $174,645 | Form 4 |
| Aug 14, 2026 | Tiffani MisencikSVP, Chief Growth Officer | Sold | 8,850 | $40.07 | $354,620 | Form 4 |
| Aug 10, 2026 | William B. MintzSVP, Chief Strategy Officer | Sold | 8,431 | $34.24 | $288,677 | Form 4 |
| Jun 9, 2026 | Nutter CarolSVP, Chief People Officer | Bought | 875 | $28.41 | $24,859 | Form 4 |
| May 19, 2026 | John Michael PrinceDirector | Bought | 10,000 | $16.00 | $160,000 | Form 4 |
| May 18, 2026 | Travis DaltonPres., CEO & Executive Chair, Director | Bought | 20,920 | $12.36 | $258,638 | Form 4 |
| May 18, 2026 | Michael KimEVP, Chief Digital Officer | Bought | 3,000 | $16.65 | $49,950 | Form 4 |
| Mar 16, 2026 | Douglas Michael GarisEvp&cfo | Bought | 1,300 | $17.69 | $22,997 | Form 4 |
| Mar 12, 2026 | Michael KimEVP, Chief Digital Officer | Bought | 15,000 | $16.50 | $247,500 | Form 4 |
| Mar 2, 2026 | Tara O'NeilSVP, General Counsel | Bought | 750 | $12.99 | $9,742 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 3 of 8 | 5 of 8 |
| Rule of 40 | −4.4% | −4.3% | 2.5% |
| Altman Z'' | 0.29 | −3.20 | −1.66 |
| Accruals ratio | −3.7% | −28.9% | −8.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 8 | 3 of 8 | 5 of 8 |
Compare
Put Claritev side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Claritev | FY25 | 3.7% | 3.0% | −1.3% | 0.5% | 9.7x | 5 | |
| Waystar | FY25 | 16.5% | 22.7% | 25.8% | 3.5% | 3.6x | 5 | Compare |
| GoodRx | FY25 | 0.6% | 11.0% | 20.6% | 5.8% | 1.4x | 6 | Compare |
| Omnicell | FY25 | 6.5% | 0.4% | 7.3% | 0.2% | −0.3x | 6 | Compare |
| Doximity | FY26 | 13.1% | 33.3% | 50.6% | 91.3% | −3.3x | 4 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 1,041 | 983 | 938 | 1,118 | 1,080 | 962 | 931 | 965 |
| Revenue growth | — | −5.6% | −4.6% | 19.2% | −3.4% | −10.9% | −3.2% | 3.7% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — |
| Operating income | 428 | 368 | −132 | 386 | −363 | 162 | −1,390 | 29 |
| Net income | 36 | 10 | −521 | 102 | −573 | −92 | −1,646 | −284 |
| Diluted EPS (US$) | 3.60 | 0.80 | −44.40 | 6.40 | −36.00 | −5.69 | −101.92 | −17.30 |
| Diluted shares (millions) | 10 | 10 | 12 | 16 | 16 | 16 | 16 | 16 |
| Cash flow | ||||||||
| Cash from operations | 292 | 284 | 377 | 405 | 372 | 172 | 108 | 117 |
| Capital expenditure | 64 | 66 | 71 | 85 | 90 | 109 | 118 | 130 |
| Free cash flow | 229 | 218 | 307 | 320 | 283 | 63 | −11 | −12 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 101 | 100 | 0 | 15 | 10 | 0 |
| Acquisitions | 0 | 0 | 140 | 0 | 0 | 0 | 0 | 5 |
| Stock-based compensation | 5 | −15 | 406 | 18 | 17 | 18 | 27 | 28 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 5 | 22 | 127 | 185 | 334 | 72 | 17 | 17 |
| Debt incl. finance leases | — | 5,397 | 4,578 | 4,972 | 4,822 | 4,600 | 4,566 | 4,612 |
| Total assets | — | 8,360 | 8,284 | 8,220 | 7,371 | 6,965 | 5,151 | 4,888 |
| Total liabilities | — | 6,375 | 5,726 | 5,876 | 5,581 | 5,256 | 5,067 | 5,056 |
| Shareholders' equity | 1,990 | 1,985 | 2,558 | 2,345 | 1,790 | 1,709 | 84 | −174 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 41.1% | 37.5% | −14.1% | 34.5% | −33.6% | 16.9% | −149.3% | 3.0% |
| Net margin | 3.5% | 1.0% | −55.5% | 9.1% | −53.1% | −9.5% | −176.8% | −29.4% |
| Free cash flow margin | 22.0% | 22.2% | 32.7% | 28.6% | 26.2% | 6.5% | −1.1% | −1.3% |
| Rule of 40 (growth + FCF margin) | — | 16.6% | 28.1% | 47.8% | 22.8% | −4.4% | −4.3% | 2.5% |
| Return on capital | — | — | −1.4% | 4.1% | −4.3% | 2.0% | −20.2% | 0.5% |
| Return on equity | — | — | −22.9% | 4.2% | −27.7% | −5.2% | −183.6% | — |
| Return on assets | — | — | −6.3% | 1.2% | −7.3% | −1.3% | −27.2% | −5.7% |
| Net debt to EBITDA | — | 7.1x | 16.9x | 6.0x | 96.4x | 7.8x | — | 9.7x |